Advertisement


Joseph A. Sparano, MD, on Stage II–III Breast Cancer and CTCs

2017 San Antonio Breast Cancer Symposium

Advertisement

Joseph A. Sparano, MD, of Montefiore Medical Center/Albert Einstein College of Medicine, discusses findings that suggest circulating tumor cells 5 years after diagnosis are prognostic for late recurrence in operable stage II–III breast cancer (Abstract GS6-03).



Related Videos

Breast Cancer

Debu Tripathy, MD, on HR+, HER2– Breast Cancer: Results From the MONALEESA-7 Trial

Debu Tripathy, MD, of The University of Texas MD Anderson Cancer Center, discusses phase III study findings on first-line ribociclib vs placebo with goserelin and tamoxifen or a no...

Breast Cancer

Sibylle Loibl, MD, PhD, on Metastatic Breast Cancer: the PADMA Trial

Sibylle Loibl, MD, PhD, of the German Breast Group, discusses a study evaluating palbociclib plus endocrine treatment vs a chemotherapy-based treatment strategy in patients with ho...

Breast Cancer

Michael Gnant, MD, on Duration of Anastrozole Treatment: Results of the ABCSG-16 Trial

Michael Gnant, MD, of the Medical University of Vienna, discusses phase III study findings on giving an additional 2 vs an additional 5 years of anastrozole after the first 5 years...

Breast Cancer

Nicholas C. Turner, MD, PhD, on Tackling Breast Cancer Diversity

Nicholas C. Turner, MD, PhD, of The Royal Marsden Hospital NHS Trust, discusses the challenges of treating metastatic breast cancer and how liquid biopsies can serve as a guide to ...

Issues in Oncology

SABCS 40th Anniversary Award Lecture: Richard Pazdur, MD, on Cancer Drug Development

Richard Pazdur, MD, of the U.S. Food & Drug Administration’s Oncology Center of Excellence, discusses the rapid changes in evaluating and approving new and effective agents, in...

Advertisement

Advertisement



Advertisement